| CASE REPORT |
|
| Year : 2021 | Volume
: 20
| Issue : 4 | Page : 401-404 |
|
|
Discordant findings of different positron emission tomography/CT tracers in a case of glioblastoma
Ram Elumalai Kumar1, Nitin Gupta1, Rajeev Ranjan2, Ritu Verma1, Ethel Shangne Belho1, Ishita Barat Sen3
1 Department of Nuclear Medicine and PET/CT, Mahajan Imaging Centre, Sir Ganga Ram Hospital, New Delhi, India
2 Department of Neurology, Sir Ganga Ram Hospital, New Delhi, India
3 Department of Nuclear Medicine and PET/CT, Fortis Memorial Research Institute, Gurugram, Haryana, India
Correspondence Address:
Dr. Nitin Gupta
Department of Nuclear Medicine and PET/CT, Mahajan Imaging Centre, Sir Ganga Ram Hospital, New Delhi - 110 060
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/wjnm.wjnm_135_20
|
|
|
18F-2-fluoro-2-deoxy-D-glucose ([18F]-FDG) positron emission tomography (PET) CT has proven useful in the evaluation of high-grade glioma and is also useful as a predictor of the degree of malignancy in newly diagnosed brain tumors. It is commonly accepted that high-grade gliomas are characterized by increased FDG uptake, whereas the low-grade glioma demonstrates reduced or absent FDG uptake. [18F]-FDOPA is an amino acid PET tracer which is a marker of the proliferative activity of brain tumors and demonstrates positive uptake in all grades of brain tumors; however, the degree of tracer uptake is significantly higher in high-grade tumors as compared to low-grade tumors. Here, we discuss a case where both FDG and DOPA PET/CT scans raised suspicion of low-grade glioma; however, the final histopathology report confirmed WHO grade IV Glioblastoma. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Users Online: 170 
